Jun Liu 2009 Science Foundation in China 17 50 doi:10.1088/1005-0841/17/2/006
Jun Liu
Show affiliationsReview
Tuberculosis (TB) continues to be a global health threat. BCG was developed as an attenuated live vaccine for tuberculosis control nearly a century ago. Despite being the most widely used vaccine in human history, BCG is not an ideal vaccine and has two major limitations: its poor efficacy against adult pulmonary TB and its disconcerting safety in immunocompromised individuals. A safer and more effective TB vaccine is urgently needed. This review article discusses current strategies to develop the next generation of TB vaccines to replace BCG. While some progresses have been made in the past decade, significant challenges lie ahead.
Issue 2 (2009)
Jun Liu 2009 Science Foundation in China 17 50
Qin Leng and Hong Yang 2009 Science Foundation in China 17 46
Li Hu et al 2009 Science Foundation in China 17 39
2009 Science Foundation in China 17 26
2009 Science Foundation in China 17 17
2009 Science Foundation in China 17 1